Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label study of simmitinib versus investigator's choice chemotherapy in advanced or metastatic esophageal squamous cell carcinoma after first-line treatment
CTR20243483Phase 3Active
- Sponsor
- Shanghai Institute of Materia Medica
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Cimetinib in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Shanghai Institute of Materia Medica. Primary endpoint: Overall survival. Started Sep 2024; status: active.
02
Drugs
Cimetinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20243483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243483.